title: Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
abstract: BACKGROUND
  Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health.
  
  
  METHODS
  To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control.
  
  
  RESULTS
  On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later.
  
  
  CONCLUSIONS
  The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
authors.affiliation: Beijing China-Japan Friendship Hospital, People's Republic of China.
authors.forename: Jiang-Tao
authors.initials: JT
authors.lastname: Lin
authors.forename: Jian-San
authors.initials: JS
authors.lastname: Zhang
authors.forename: Nan
authors.initials: N
authors.lastname: Su
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Xu
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.forename: Jiang-Ting
authors.initials: JT
authors.lastname: Chen
authors.forename: Xin
authors.initials: X
authors.lastname: Chen
authors.forename: Yu-Xuan
authors.initials: YX
authors.lastname: Liu
authors.forename: Hong
authors.initials: H
authors.lastname: Gao
authors.forename: Yu-Ping
authors.initials: YP
authors.lastname: Jia
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Sun
authors.forename: Xu
authors.initials: X
authors.lastname: Wang
authors.forename: Dong-Zheng
authors.initials: DZ
authors.lastname: Yu
authors.forename: Rong
authors.initials: R
authors.lastname: Hai
authors.forename: Qiang
authors.initials: Q
authors.lastname: Gao
authors.forename: Ye
authors.initials: Y
authors.lastname: Ning
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Wang
authors.forename: Ma-Chao
authors.initials: MC
authors.lastname: Li
authors.forename: Biao
authors.initials: B
authors.lastname: Kan
authors.forename: Guan-Mu
authors.initials: GM
authors.lastname: Dong
authors.forename: Qi
authors.initials: Q
authors.lastname: An
authors.forename: Ying-Qun
authors.initials: YQ
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Han
authors.forename: Chuan
authors.initials: C
authors.lastname: Qin
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Yin
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Dongs
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009500:Neutralization Tests; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology* / Q000628:therapy* / Q000821:virology; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines